Leukemia Drug AMX-883 to Present Data in December
Amphista's BRD9 protein degrader will be shown at the December 12-15 ASH meeting, with clinical results still pending.
Updated on Nov. 5, 2026 in Biotech

Amphista Therapeutics, a Cambridge-based biopharma company, has had its lead candidate AMX-883 accepted for an oral presentation at the American Society of Hematology Annual Meeting in New Orleans, scheduled for December 12-15. AMX-883 is at the research and clinical-trial stage, not an approved product.
Why it matters
The presentation will bring clinical data on a protein-degradation approach to acute myeloid leukemia, a field where targeted, non-traditional drug mechanisms are being actively explored. The timing places the data before a major hematology audience ahead of a planned follow-on abstract in the ASH Blood Supplement.
The presentation is an oral abstract from the BRAMLIE trial, an open-label, multi-part dose-escalation and optimisation study of AMX-883. No measured efficacy or safety figures are available yet, so the demonstrated performance of the compound cannot be characterized at this stage.
The players
Amphista Therapeutics
A Cambridge-based biopharma company spun out of the University of Dundee, focused on non-cereblon and VHL targeted protein degradation medicines, with AMX-883 as its lead candidate.
Dr Louise Modis
The chief executive of Amphista Therapeutics, who will present the AMX-883 data at the American Society of Hematology Annual Meeting.
American Society of Hematology
The professional society for blood-disease researchers and clinicians, whose annual meeting is a major venue for hematology and leukemia data.
The details
AMX-883 is a targeted protein degrader, a class of drugs that tags a disease-driving protein so the cell's own disposal machinery breaks it down. Amphista's compound targets BRD9, a protein that helps control transcription factor programs, which are the gene-switching instructions that keep leukemic cells in an immature state. According to the company's data framing, degrading BRD9 releases this differentiation block and reduces the frequency of leukemic stem cells. The approach is described as targeting non-cereblon and VHL pathways, two of the cellular ligase systems that protein-degrader drugs commonly use to mark their targets.
Timeline
The American Society of Hematology Annual Meeting runs December 12-15 in New Orleans.
Dr Louise Modis is scheduled to present the AMX-883 data at the meeting.
The Tech Race
Targeted protein degradation is a growing area of drug development in which several companies are pursuing degraders against different protein targets. AMX-883 places Amphista among the groups testing this mechanism against BRD9 in acute myeloid leukemia, a competitive field where the ASH meeting is a key venue for comparing early clinical signals.
AMX-883 is an investigational compound with no approval or commercial availability, so patients cannot access it from this presentation alone. Any path to treatment would depend on later trial results and regulatory review, and no timeline for that has been announced.
The takeaway
Watch the December 12-15 ASH presentation and the forthcoming ASH Blood Supplement abstract for the first reported BRAMLIE efficacy and safety figures. Those results will show whether BRD9 degradation produces the differentiation effect the company describes in leukemic cells.
What happens next
The second AMX-883 BRAMLIE abstract is due to be published in the ASH Blood Supplement, and the oral presentation is scheduled for the December 12-15 meeting in New Orleans.
Further reading
For broader context on how new drug mechanisms reach clinic, browse our Biotech coverage.





